人类恶性黑色素瘤的细胞表面抗原。II. 免疫黏附试验的血清学分型及两种新表面抗原的定义
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
作者信息
Shiku H, Takahashi T, Oettgen H F
出版信息
J Exp Med. 1976 Oct 1;144(4):873-81. doi: 10.1084/jem.144.4.873.
Abstract
Immune adherence assays revealed that 10 out of 18 melanoma patients had demonstrable antibody to surface antigens of autologous cultured melanoma cells, with serum titers ranging from 1/4 to 1/160. Autologous fibroblasts showed no reactions with these sera. Antibody from individual patients showed reproducible temperature preference for maximal reactivity. Two new melanoma antigenic systems were defined in this study. The first, BD, was restricted to autologous melanoma and could not be demonstrated in absorption tests on 12 allogeneic melanoma cell lines. The other, AH, was found on 5 of 12 melanomas and represents a class of shared melanoma surface antigens. Neither BD nor AH antigen was found on normal cells from autologous, allogeneic, or xenogeneic sources or on any nonmelanoma tumor cell line. Methods are now available to develop a comprehensive serological classification of the surface antigens of melanoma.
摘要
免疫黏附试验显示，18名黑色素瘤患者中有10名对自体培养的黑色素瘤细胞表面抗原有可检测到的抗体，血清滴度范围为1/4至1/160。自体成纤维细胞与这些血清无反应。来自个体患者的抗体显示出对最大反应性具有可重复的温度偏好。本研究定义了两个新的黑色素瘤抗原系统。第一个是BD，仅限于自体黑色素瘤，在对12种同种异体黑色素瘤细胞系的吸收试验中未得到证实。另一个是AH，在12种黑色素瘤中的5种中发现，代表一类共享的黑色素瘤表面抗原。在来自自体、同种异体或异种来源的正常细胞以及任何非黑色素瘤肿瘤细胞系上均未发现BD或AH抗原。现在已有方法可用于对黑色素瘤表面抗原进行全面的血清学分类。
相似文献
1
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.人类恶性黑色素瘤的细胞表面抗原。II. 免疫黏附试验的血清学分型及两种新表面抗原的定义
J Exp Med. 1976 Oct 1;144(4):873-81. doi: 10.1084/jem.144.4.873.
2
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.对正常人进行黑色素瘤细胞表面抗原天然抗体的血清学调查。
Proc Natl Acad Sci U S A. 1980 Jul;77(7):4260-4. doi: 10.1073/pnas.77.7.4260.
3
Serological analysis of cell surface antigens of malignant human brain tumors.恶性人脑肿瘤细胞表面抗原的血清学分析
Proc Natl Acad Sci U S A. 1978 Oct;75(10):5122-6. doi: 10.1073/pnas.75.10.5122.
4
Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody.人类黑色素瘤的1类（独特）肿瘤抗原。通过自身抗体鉴定一种90,000道尔顿的细胞表面糖蛋白。
J Exp Med. 1984 Oct 1;160(4):1219-33. doi: 10.1084/jem.160.4.1219.
5
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens.源自同一患者不同黑色素瘤转移灶的细胞系表面抗原和糖蛋白表达的异质性。对肿瘤抗原研究的启示。
J Exp Med. 1981 Dec 1;154(6):1764-78. doi: 10.1084/jem.154.6.1764.
6
[Serological analysis of melanoma patients receiving autologous melanoma cell vaccines].[接受自体黑色素瘤细胞疫苗的黑色素瘤患者的血清学分析]
Gan To Kagaku Ryoho. 1983 Feb;10(2 Pt):261-72.
7
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.人类恶性黑色素瘤的细胞表面抗原：针对培养的自体黑色素瘤细胞体液免疫的混合血细胞吸附试验
Proc Natl Acad Sci U S A. 1976 Sep;73(9):3278-82. doi: 10.1073/pnas.73.9.3278.
8
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics.人类恶性黑色素瘤的细胞表面抗原。III. 对具有异常特征的自身抗体的识别
J Exp Med. 1977 Mar 1;145(3):784-9. doi: 10.1084/jem.145.3.784.
9
10
Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients.建立配对肿瘤细胞和自体病毒转化细胞系以确定黑色素瘤和肉瘤患者的体液免疫反应。
Int J Cancer. 1978 Mar 15;21(3):299-306. doi: 10.1002/ijc.2910210308.
引用本文的文献
1
Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.癌症中的自身抗体：最常见癌症中其临床作用的系统评价。
Front Immunol. 2024 Aug 21;15:1455602. doi: 10.3389/fimmu.2024.1455602. eCollection 2024.
2
In vitro antiproliferative and apoptotic effects of thiosemicarbazones based on (-)-camphene and R-(+)-limonene in human melanoma cells.基于（-）-莰烯和 R-（+）-柠檬烯的噻唑烷酮类化合物对人黑色素瘤细胞的体外增殖抑制和凋亡作用。
PLoS One. 2023 Nov 30;18(11):e0295012. doi: 10.1371/journal.pone.0295012. eCollection 2023.
3
Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD-Targeted CAR-NK Cells and Mediates Potent Cell Killing in the Absence of IL-2.IL-15超级激动剂的共表达促进靶向GD的CAR-NK细胞的自我富集，并在没有IL-2的情况下介导有效的细胞杀伤。
Cancers (Basel). 2023 Aug 29;15(17):4310. doi: 10.3390/cancers15174310.
4
Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer.癌症睾丸抗原的生物学特性及其在癌症治疗中的意义。
Cells. 2023 Mar 17;12(6):926. doi: 10.3390/cells12060926.
5
VEGF-A promotes the motility of human melanoma cells through the VEGFR1-PI3K/Akt signaling pathway.VEGF-A 通过 VEGFR1-PI3K/Akt 信号通路促进人黑色素瘤细胞的迁移。
In Vitro Cell Dev Biol Anim. 2022 Sep;58(8):758-770. doi: 10.1007/s11626-022-00717-3. Epub 2022 Aug 23.
6
Lysosomal Zn release triggers rapid, mitochondria-mediated, non-apoptotic cell death in metastatic melanoma.溶酶体锌释放触发转移性黑色素瘤中快速的、线粒体介导的、非凋亡性细胞死亡。
Cell Rep. 2021 Oct 19;37(3):109848. doi: 10.1016/j.celrep.2021.109848.
7
The genealogy of SEREX.SEREX的谱系。
Cancer Immun. 2012;12:7. Epub 2012 May 1.
8
Autologous typing: a tedious but orthodox approach for defining human tumor antigens with clarity.自体分型：一种明确界定人类肿瘤抗原的繁琐但正统的方法。
Cancer Immun. 2012;12:3. Epub 2012 May 1.
9
Use of liposomes as drug delivery vehicles for treatment of melanoma.脂质体作为治疗黑色素瘤的药物递送载体的应用。
Pigment Cell Melanoma Res. 2009 Aug;22(4):388-99. doi: 10.1111/j.1755-148X.2009.00581.x. Epub 2009 May 22.
10
Intratumoral immunotherapy: using the tumour against itself.瘤内免疫疗法：利用肿瘤自身对抗肿瘤
Immunology. 2005 Jan;114(1):11-22. doi: 10.1111/j.1365-2567.2004.02001.x.
本文引用的文献
1
Isoantigens of the H-2 and Tla loci of the mouse: interactions affecting their representation on thymocytes.小鼠H-2和Tla位点的同种抗原：影响其在胸腺细胞上表达的相互作用。
J Exp Med. 1968 Jul 1;128(1):85-95. doi: 10.1084/jem.128.1.85.
2
Detection of cell surface antigens on monolayer cells. I. The application of immune adherence on a micro scale.单层细胞表面抗原的检测。I. 微量免疫黏附的应用。
Immunology. 1970 Nov;19(5):771-82.
3
Human malignant melanoma antibodies demonstrated by immunofluorescence.通过免疫荧光法显示的人类恶性黑色素瘤抗体。
Arch Surg. 1970 Apr;100(4):491-7. doi: 10.1001/archsurg.1970.01340220167028.
4
Anti-tumor immunoreactivity in patients with malignant melanoma.恶性黑色素瘤患者的抗肿瘤免疫反应性。
Med J Aust. 1972 Feb 26;1(9):397-403.
5
The G (Gross) leukemia antigen.G（总）白血病抗原。
Cancer Res. 1965 Jul;25(6):813-9.
6
Demonstration of antibodies against human malignant melanoma by immunofluorescence.通过免疫荧光法显示抗人恶性黑色素瘤抗体
Surgery. 1968 Jul;64(1):233-40.
7
Possible immunological factors in human malignant melanoma in Uganda.乌干达人类恶性黑色素瘤中可能存在的免疫因素。
Lancet. 1967 Oct 28;2(7522):921-2. doi: 10.1016/s0140-6736(67)90236-x.
8
The specificity of surface membrane immunofluorescence in human malignant melanoma.人恶性黑色素瘤表面膜免疫荧光的特异性
Int J Cancer. 1972 Jul 15;10(1):105-11. doi: 10.1002/ijc.2910100114.
9
Clinical and immunological significance of human melanoma cytotoxic antibody.人类黑色素瘤细胞毒性抗体的临床与免疫学意义
Cancer Res. 1975 Jan;35(1):189-93.
10
Antibodies and antigen expression in human melanoma detected by the immune adherence test.通过免疫黏附试验检测人黑色素瘤中的抗体和抗原表达。
Int J Cancer. 1975 Dec 15;16(6):981-97. doi: 10.1002/ijc.2910160612.
Zotero 插件